169 related articles for article (PubMed ID: 33767345)
21. Using benefit-cost ratio to select Universal Newborn Hearing Screening test criteria.
Porter HL; Neely ST; Gorga MP
Ear Hear; 2009 Aug; 30(4):447-57. PubMed ID: 19455038
[TBL] [Abstract][Full Text] [Related]
22. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model.
Cipriano LE; Rupar CA; Zaric GS
Value Health; 2007; 10(2):83-97. PubMed ID: 17391418
[TBL] [Abstract][Full Text] [Related]
23. Pediatric imaging in DICER1 syndrome.
Bueno MT; Martínez-Ríos C; la Puente Gregorio A; Ahyad RA; Villani A; Druker H; van Engelen K; Gallinger B; Aronoff L; Grant R; Malkin D; Greer MC
Pediatr Radiol; 2017 Sep; 47(10):1292-1301. PubMed ID: 28474256
[TBL] [Abstract][Full Text] [Related]
24. Newborn hearing concurrent gene screening can improve care for hearing loss: a study on 14,913 Chinese newborns.
Wang QJ; Zhao YL; Rao SQ; Guo YF; He Y; Lan L; Yang WY; Zheng QY; Ruben RJ; Han DY; Shen Y
Int J Pediatr Otorhinolaryngol; 2011 Apr; 75(4):535-42. PubMed ID: 21329993
[TBL] [Abstract][Full Text] [Related]
25. Incidence of Neonatal Developmental Dysplasia of the Hip and Late Detection Rates Based on Screening Strategy: A Systematic Review and Meta-analysis.
Kuitunen I; Uimonen MM; Haapanen M; Sund R; Helenius I; Ponkilainen VT
JAMA Netw Open; 2022 Aug; 5(8):e2227638. PubMed ID: 35980635
[TBL] [Abstract][Full Text] [Related]
26. DICER1 screening in 15 paediatric paratesticular sarcomas unveils an unusual DICER1-associated sarcoma.
Apellaniz-Ruiz M; Cullinan N; Grant R; Marrano P; Priest JR; Thorner PS; Goudie C; Foulkes WD
J Pathol Clin Res; 2020 Jul; 6(3):185-194. PubMed ID: 32222066
[TBL] [Abstract][Full Text] [Related]
27. Predominant
Lee YA; Im SW; Jung KC; Chung EJ; Shin CH; Kim JI; Park YJ
Thyroid; 2020 Aug; 30(8):1120-1131. PubMed ID: 32228164
[No Abstract] [Full Text] [Related]
28. Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis.
Zhang L; Bao Y; Riaz M; Tiller J; Liew D; Zhuang X; Amor DJ; Huq A; Petelin L; Nelson M; James PA; Winship I; McNeil JJ; Lacaze P
Genet Med; 2019 Sep; 21(9):1958-1968. PubMed ID: 30773532
[TBL] [Abstract][Full Text] [Related]
29. Neoplasm Risk Among Individuals With a Pathogenic Germline Variant in DICER1.
Stewart DR; Best AF; Williams GM; Harney LA; Carr AG; Harris AK; Kratz CP; Dehner LP; Messinger YH; Rosenberg PS; Hill DA; Schultz KAP
J Clin Oncol; 2019 Mar; 37(8):668-676. PubMed ID: 30715996
[TBL] [Abstract][Full Text] [Related]
30. Rare Germline
Martínez de LaPiscina I; Hernández-Ramírez LC; Portillo N; Gómez-Gila AL; Urrutia I; Martínez-Salazar R; García-Castaño A; Aguayo A; Rica I; Gaztambide S; Faucz FR; Keil MF; Lodish MB; Quezado M; Pankratz N; Chittiboina P; Lane J; Kay DM; Mills JL; Castaño L; Stratakis CA
Front Endocrinol (Lausanne); 2020; 11():433. PubMed ID: 32714280
[No Abstract] [Full Text] [Related]
31. Cost and cost-effectiveness of universal screening for hearing loss in newborns.
Kezirian EJ; White KR; Yueh B; Sullivan SD
Otolaryngol Head Neck Surg; 2001 Apr; 124(4):359-67. PubMed ID: 11283492
[TBL] [Abstract][Full Text] [Related]
32. Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors.
Custódio G; Parise GA; Kiesel Filho N; Komechen H; Sabbaga CC; Rosati R; Grisa L; Parise IZ; Pianovski MA; Fiori CM; Ledesma JA; Barbosa JR; Figueiredo FR; Sade ER; Ibañez H; Arram SB; Stinghen ST; Mengarelli LR; Figueiredo MM; Carvalho DC; Avilla SG; Woiski TD; Poncio LC; Lima GF; Pontarolo R; Lalli E; Zhou Y; Zambetti GP; Ribeiro RC; Figueiredo BC
J Clin Oncol; 2013 Jul; 31(20):2619-26. PubMed ID: 23733769
[TBL] [Abstract][Full Text] [Related]
33. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis.
Mahadevia PJ; Fleisher LA; Frick KD; Eng J; Goodman SN; Powe NR
JAMA; 2003 Jan; 289(3):313-22. PubMed ID: 12525232
[TBL] [Abstract][Full Text] [Related]
34. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.
de Andrade KC; Khincha PP; Hatton JN; Frone MN; Wegman-Ostrosky T; Mai PL; Best AF; Savage SA
Lancet Oncol; 2021 Dec; 22(12):1787-1798. PubMed ID: 34780712
[TBL] [Abstract][Full Text] [Related]
35. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
[TBL] [Abstract][Full Text] [Related]
37. Presacral malignant teratoid neoplasm in association with pathogenic DICER1 variation.
Nakano Y; Hasegawa D; Stewart DR; Schultz KAP; Harris AK; Hirato J; Uemura S; Tamura A; Saito A; Kawamura A; Yoshida M; Yamasaki K; Yamashita S; Ushijima T; Kosaka Y; Ichimura K; Dehner LP; Hill DA
Mod Pathol; 2019 Dec; 32(12):1744-1750. PubMed ID: 31296931
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome.
Tak CR; Biltaji E; Kohlmann W; Maese L; Hainaut P; Villani A; Malkin D; Sherwin CMT; Brixner DI; Schiffman JD
Pediatr Blood Cancer; 2019 May; 66(5):e27629. PubMed ID: 30719841
[TBL] [Abstract][Full Text] [Related]
39. Clinical and economic evaluation of a proteomic biomarker preterm birth risk predictor: cost-effectiveness modeling of prenatal interventions applied to predicted higher-risk pregnancies within a large and diverse cohort.
Burchard J; Markenson GR; Saade GR; Laurent LC; Heyborne KD; Coonrod DV; Schoen CN; Baxter JK; Haas DM; Longo SA; Sullivan SA; Wheeler SM; Pereira LM; Boggess KA; Hawk AF; Crockett AH; Treacy R; Fox AC; Polpitiya AD; Fleischer TC; Garite TJ; Jay Boniface J; Zupancic JAF; Critchfield GC; Kearney PE
J Med Econ; 2022; 25(1):1255-1266. PubMed ID: 36377363
[TBL] [Abstract][Full Text] [Related]
40. Surveillance recommendations for DICER1 pathogenic variant carriers: a report from the SIOPE Host Genome Working Group and CanGene-CanVar Clinical Guideline Working Group.
Bakhuizen JJ; Hanson H; van der Tuin K; Lalloo F; Tischkowitz M; Wadt K; Jongmans MCJ; ; ;
Fam Cancer; 2021 Oct; 20(4):337-348. PubMed ID: 34170462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
